Zinbryta® (daclizumab) – Drug withdrawal
March 2, 2018 - Biogen and AbbVie announced the voluntary worldwide withdrawal of marketing authorizations for Zinbryta (daclizumab) due to the nature and complexity of adverse events being reported with Zinbryta use.
Download PDF
